$AbCellera Biologics(ABCL)$ vi

$AbCellera Biologics(ABCL)$ view order details.@Trade Feed Decoder

ABCL

07-18 23:58

USAbCellera Biologics

Side	Price \| Filled	Realized P&L
Buy Open	4.66 25	-19.52% Holding

AbCellera Biologics

Trade Feed: Who is your favorite trader?

Come to the Trade Feed Topic to find more trading opportunities! Also, please feel free to recommend and introduce fellow Tigers to the "hidden gem traders" that you've discovered!

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

Trade Feed Decoder
07-19
Trade Feed Decoder
The ABCL trade reflects a BUY position in a biotech firm known for its antibody discovery platform. The -3.1% P&L suggests near-term volatility, common in preclinical-stage biotech stocks where valuations hinge on pipeline progress rather than current revenue. At $4.66/share, the entry likely aimed to capitalize on depressed valuations after sector-wide 2022-2023 declines. However, the loss underscores the challenge of timing entries in cash-intensive biotechs facing dilution risks and binary clinical catalysts. Traders might evaluate whether the rationale aligns with event-driven strategies (e.g., upcoming data readouts) or a contrarian value play. Position sizing here would be critical given the stock's 52-week range ($3.18-$6.90), requiring tight risk parameters for such asymmetric outcomes.

Leave a comment

{"i18n":{"language":"en_US"},"detailType":1,"isChannel":false,"data":{"magic":2,"id":458066562388520,"tweetId":"458066562388520","gmtCreate":1752854403430,"gmtModify":1766534857635,"author":{"id":3555385233204730,"idStr":"3555385233204730","authorId":3555385233204730,"authorIdStr":"3555385233204730","name":"Kishores","avatar":"https://static.tigerbbs.com/da74a1b82af0023364b295cfe599f7bd","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":12,"crmLevelSwitch":0,"currentWearingBadge":{"badgeId":"1026c425416b44e0aac28c11a0848493-4","templateUuid":"1026c425416b44e0aac28c11a0848493","name":"Tiger Star","description":"Join the tiger community for 2000 days","bigImgUrl":"https://static.tigerbbs.com/dddf24b906c7011de2617d4fb3f76987","smallImgUrl":"https://static.tigerbbs.com/53d58ad32c97254c6f74db8b97e6ec49","grayImgUrl":"https://static.tigerbbs.com/6304700d92ad91c7a33e2e92ec32ecc1","redirectLinkEnabled":0,"hasAllocated":1,"isWearing":1,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2025.12.08","individualDisplayEnabled":0},"individualDisplayBadges":[],"fanSize":1035,"starInvestorFlag":true,"fullDisclosureFlag":true,"starInvestorFollowerNum":1024,"starInvestorOrderShareNum":452,"userFollowInvestorFlag":false,"orderNotificationFlag":false,"ror":188.63,"showRor":true,"winRationPercentage":57.77027,"tradeVolumeEst":0},"themes":[{"themeId":"4e1ab37448a24dd39b7882426fc6fd27","categoryId":"ab3d937a5fd848c08008411a9be702b5","name":"Trade Feed: Who is your favorite trader?","type":0,"rnLink":"https://laohu8.com/RN?name=RNTheme&page=/theme/detail&rndata={\"themeId\":4e1ab37448a24dd39b7882426fc6fd27}&rnconfig={\"headerBarHidden\": true}","description":"Come to the Trade Feed Topic to find more trading opportunities! Also, please feel free to recommend and introduce fellow Tigers to the \"hidden gem traders\" that you've discovered!","image":"https://community-static.tradeup.com/news/e496e574dd744490c7b4f7959f83f5a4"}],"images":[],"coverImages":[],"html":"<html><head></head><body><a href=\"https://ttm.financial/S/ABCL\">$AbCellera Biologics(ABCL)$&nbsp;</a>view order details.<a href=\"https://ttm.financial/U/10000000000011061\">@Trade Feed Decoder</a></body></html>","htmlText":"<html><head></head><body><a href=\"https://ttm.financial/S/ABCL\">$AbCellera Biologics(ABCL)$&nbsp;</a>view order details.<a href=\"https://ttm.financial/U/10000000000011061\">@Trade Feed Decoder</a></body></html>","text":"$AbCellera Biologics(ABCL)$ view order details.@Trade Feed Decoder","highlighted":1,"essential":1,"paper":1,"likeSize":99,"commentSize":1,"repostSize":69,"favoriteSize":0,"link":"https://ttm.financial/post/458066562388520","repostId":0,"isVote":1,"tweetType":1,"viewCount":2825,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":["ABCL"],"verified":2,"subType":0,"readableState":1,"langContent":"EN","currentLanguage":"EN","warmUpFlag":false,"orderFlag":true,"orderData":{"uuid":"3555385233204730","orderId":"39840001927025664","kind":"TRADE","symbol":"ABCL","secType":"STK","symbolHtmlTag":"<a href=\"https://ttm.financial/S/ABCL\">$AbCellera Biologics(ABCL)$&nbsp;</a>","symbolHtmlTagHref":"https://ttm.financial/S/ABCL","symbolName":"AbCellera Biologics","market":"US","action":"BUY","currency":"USD","symbolLogo":"","showFilledQuantity":true,"nameCN":"AbCellera Biologics","orderType":"LMT","filledQuantityFinal":25,"avgFillPrice":4.66,"createTime":1752854293,"filledQuantity":"25","filledQuantityScale":"0","openFlag":true,"side":"DEBIT","contractMajorDescription":"AbCellera Biologics","contractExtraDescription":"ABCL","legs":[],"completedFlag":false,"orderPnl":{"openRealizedPnlPercent":0,"openUnrealizedPnlPercent":-0.1952},"quickOrderFlag":false},"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":["订单分享帖","未分享订单分享帖"],"commentAndTweetFlag":false,"andRepostAutoSelectedFlag":false,"upFlag":false,"length":34,"optionInvolvedFlag":false,"xxTargetLangEnum":"ORIG"},"commentList":[{"id":458023131304136,"commentId":"458023131304136","gmtCreate":1752858934255,"gmtModify":1752859284962,"authorId":10000000000011060,"author":{"id":10000000000011060,"idStr":"10000000000011061","authorId":10000000000011060,"name":"Trade Feed Decoder","avatar":"https://community-static.tradeup.com/news/4dc8fec78bad5acffbf563bdbc6bc8ed","vip":4,"crmLevel":1,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":458066562388520,"objectIdStr":"458066562388520","type":1,"supId":0,"supIdStr":"0","prevId":0,"prevIdStr":"0","content":"The ABCL trade reflects a BUY position in a biotech firm known for its antibody discovery platform. The -3.1% P&amp;L suggests near-term volatility, common in preclinical-stage biotech stocks where valuations hinge on pipeline progress rather than current revenue. At $4.66/share, the entry likely aimed to capitalize on depressed valuations after sector-wide 2022-2023 declines. However, the loss underscores the challenge of timing entries in cash-intensive biotechs facing dilution risks and binary clinical catalysts. Traders might evaluate whether the rationale aligns with event-driven strategies (e.g., upcoming data readouts) or a contrarian value play. Position sizing here would be critical given the stock's 52-week range ($3.18-$6.90), requiring tight risk parameters for such asymmetric outcomes.","text":"The ABCL trade reflects a BUY position in a biotech firm known for its antibody discovery platform. The -3.1% P&amp;L suggests near-term volatility, common in preclinical-stage biotech stocks where valuations hinge on pipeline progress rather than current revenue. At $4.66/share, the entry likely aimed to capitalize on depressed valuations after sector-wide 2022-2023 declines. However, the loss underscores the challenge of timing entries in cash-intensive biotechs facing dilution risks and binary clinical catalysts. Traders might evaluate whether the rationale aligns with event-driven strategies (e.g., upcoming data readouts) or a contrarian value play. Position sizing here would be critical given the stock's 52-week range ($3.18-$6.90), requiring tight risk parameters for such asymmetric outcomes.","html":"The ABCL trade reflects a BUY position in a biotech firm known for its antibody discovery platform. The -3.1% P&amp;L suggests near-term volatility, common in preclinical-stage biotech stocks where valuations hinge on pipeline progress rather than current revenue. At $4.66/share, the entry likely aimed to capitalize on depressed valuations after sector-wide 2022-2023 declines. However, the loss underscores the challenge of timing entries in cash-intensive biotechs facing dilution risks and binary clinical catalysts. Traders might evaluate whether the rationale aligns with event-driven strategies (e.g., upcoming data readouts) or a contrarian value play. Position sizing here would be critical given the stock's 52-week range ($3.18-$6.90), requiring tight risk parameters for such asymmetric outcomes.","likeSize":0,"commentSize":0,"subComments":[],"verified":10,"allocateAmount":0,"commentType":"hot","coins":0,"score":0,"disclaimerFlag":true,"disclaimerType":1,"specialCommentTag":"AI_ANALYSE"}],"isCommentEnd":false,"isTiger":false,"isWeiXinMini":false,"url":"/m/post/458066562388520"}